MBOT Stock Risk & Deep Value Analysis
Microbot Medical Inc
Healthcare • Medical Instruments & Supplies
DVR Score
out of 10
What You Need to Know About MBOT Stock
We analyzed Microbot Medical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MBOT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is MBOT Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for MBOT?
- ⚠
Failure to secure additional funding within 6 months
- ⚠
Slower-than-expected commercial adoption of LIBERTY system
- ⚠
Intensified competition from larger players or new market entrants
Unlock MBOT Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Microbot Medical Inc (MBOT) Do?
Market Cap
$122.90M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
20
Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
Visit Microbot Medical Inc WebsiteIs MBOT Stock Undervalued?
Unlock the full AI analysis for MBOT
Get the complete DVR score, risk analysis, and more
Does MBOT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily built on its proprietary technology and regulatory approvals. It will persist and strengthen if Microbot continues to innovate, expand its patent portfolio, successfully integrate its system into hospital workflows (creating switching costs), and gain significant user adoption before major competitors develop comparable solutions.
Moat Erosion Risks
- •Competitors developing superior or cheaper robotic endovascular solutions
- •Patent expiration or successful challenges to existing IP
- •Slow adoption due to high upfront costs or training requirements
MBOT Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive MBOT Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Expected late March/early April 2026)
- •Announcement of new financing round or significant grant
- •Initial pilot program results or early commercial sales data
Medium-Term (6-18 months)
- •Expansion of distribution network or new strategic partnership
- •Additional pre-clinical or clinical data releases for new indications/features
- •Regulatory clearances for international markets
Long-Term (18+ months)
- •Establishment as a market leader in robotic endovascular surgery
- •Potential acquisition by a larger medical device company
- •Development of next-generation robotic platforms
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MBOT?
- ✓
Announcement of a new non-dilutive financing round or significant equity raise
- ✓
Acceleration in LIBERTY system sales and recurring revenue growth
- ✓
Expansion of strategic partnerships and distribution channels
Bull Case Analysis
See what could go right with Premium
Compare MBOT to Similar Stocks
See how Microbot Medical Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MBOT (Microbot Medical Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
